Archford Capital Strategies LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 90.8% in the second quarter, according to its most recent filing with the SEC. The firm owned 2,236 shares of the company’s stock after selling 22,047 shares during the quarter. Archford Capital Strategies LLC’s holdings in Johnson & Johnson were worth $198,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Harding Loevner LP acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the period. Lenox Wealth Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares during the period. Mountain Capital Investment Advisors Inc acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $124,000. Finally, Shine Investment Advisory Services Inc. acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $177,000. Institutional investors own 65.89% of the company’s stock.

JNJ has been the subject of several research analyst reports. Cowen set a $147.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a report on Thursday, August 24th. UBS restated an “underweight” rating on shares of Johnson & Johnson in a report on Thursday, August 24th. BMO Capital Markets restated a “buy” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a report on Friday, September 1st. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price objective for the company. in a report on Monday, September 18th. Finally, Goldman Sachs Group lowered Johnson & Johnson from a “neutral” rating to a “sell” rating and upped their price objective for the company from $125.00 to $130.00 in a report on Wednesday, September 20th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $145.04.

Shares of Johnson & Johnson (NYSE JNJ) traded up $0.39 during trading on Friday, hitting $142.04. The stock had a trading volume of 4,929,567 shares, compared to its average volume of 5,869,776. The firm has a market capitalization of $383,984.28, a price-to-earnings ratio of 20.02, a PEG ratio of 2.90 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 12 month low of $110.76 and a 12 month high of $144.35.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.68 earnings per share. equities analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.37%. The ex-dividend date of this dividend was Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/12/15/archford-capital-strategies-llc-has-198000-holdings-in-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.